Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients

• DOI: 10.1371/annotation/0c66099f-d115-464e-95f3-f3b9412a325a
• Publication Date: 2013-02-23T21:47:55Z
• Authors: Gaia Schiavon; Alessandro Ruggiero; Patrick Schöffski; Bronno van der Holt; Dave J. Bekers; Karel Eechoute; Vincent Vandecaveye; Gabriel P. Krestin; Jaap Verweij; Stefan Sleijfer; Ron H. J. Mathijssen
• Keywords: Imatinib Mesylate

Background: Assessment of tumor size changes is crucial in clinical trials and patient care.We compared imatinib-induced volume liver metastases (LM) from gastro-intestinal stromal tumors (GIST) to RECIST Choi criteria their association with overall survival (OS).Methods: LM 84 GIST patients (training validation set) were evaluated using manual semi-automated Computed Tomography measurements at baseline, after 3, 6 12 months imatinib.The ability uni-dimensional (1D) three-dimensional (3D) detect (increase/decrease) $20% was evaluated.Volumetric response cut-offs derived minimally relevant (+20/230%) by RECIST, considering lesions as spherical or ellipsoidal.Results: 3D detected more frequently than 1D every time-point (P#0.008).3D registered responses 3 for 3D-spheres (P#0.03) all time-points 3D-ellipsoids (P,0.001).Progressive disease seems better correlate OS late timepoints other criteria. Conclusion:Volume (especially ellipsoids) classify a higher number imatinib-responders RECIST.Volume discriminates diameter constitutes feasible robust method evaluate predict benefit.